ArticleEuropean journal of hospital pharmacy : science and practice2021
Bullous pemphigoid induced by ustekinumab: a case report.
Article in European journal of hospital pharmacy : science and practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- Recent advances in the genetics and innate immune cells of bullous pemphigoid.Frontiers in immunology · 2025Review
- Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update.American journal of clinical dermatology · 2024Review
- Causal association between psoriasis vulgaris and bullous pemphigoid: a two-sample bidirectional Mendelian randomization study.Frontiers in immunology · 2024Article
- Advancing Treatment in Bullous Pemphigoid: A Comprehensive Review of Novel Therapeutic Targets and Approaches.Clinical reviews in allergy & immunology · 2023Review
- Development of bullous pemphigoid during treatment of psoriasis with ustekinumab: a case report and literature review.Frontiers in medicine · 2023Article
- The Intriguing Links between Psoriasis and Bullous Pemphigoid.Journal of clinical medicine · 2022Review
- Management of Coexisting Bullous Pemphigoid and Psoriasis: A Review.American journal of clinical dermatology · 2022Review
- A Review of the Immunologic Pathways Involved in Bullous Pemphigoid and Novel Therapeutic Targets.Journal of clinical medicine · 2022Review
- Pemphigus and Pemphigoid: From Disease Mechanisms to Druggable Pathways.The Journal of investigative dermatology · 2022Review
- Guselkumab-associated bullous pemphigoid in a psoriasis patient: A case report and review of the literature.Dermatologic therapy · 2022Review
- Paradoxical phenomena of bullous pemphigoid induced and treated by identical biologics.Frontiers in immunology · 2022Review
- Ulcerative colitis induced by ixekizumab: a case report.European journal of hospital pharmacy : science and practice · 2021Article
- Sequential Treatment of Generalized Pustular Psoriasis Combined with Bullous Pemphigoid Using Spesolimab and Dupilumab: A Case Report and Literature Review.Case reports in dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A possible case of bullous pemphigoid (BP) that developed during treatment with ustekinumab is reported. Ustekinumab is a human monoclonal antibody found in pathologies such as psoriasis, which works by inhibiting the activity of interleukin-12 and interleukin-23. We describe the case of a 75-year-old woman who presented with new onset of erythematous and bullous lesions 5 days after receiving a fifth dose of ustekinumab. The patient was treated with corticosteroids and dapsone, whereupon the lesions disappeared. Ustekinumab was withdrawn. Currently the patient remains asymptomatic. In addition, the histopathological and immunofluorescence findings confirmed the diagnosis of BP. Three causality algorithms were applied and revealed a probable causal relationship. There may be a causal relationship between the use of ustekinumab and BP. This association should be taken into account by physicians when prescribing and reviewing drug therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.